Drugs

Dec 24, 2024, 14:29

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma

Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:

“Advanced urothelial carcinoma patients with TSC1 mutations show higher response rates to EV monotherapy (87% vs. 51%), while presence of CDKN2A/B is neg associated with PFS (4.6 vs. 6 ) mo. (Nectin4 is not available).”

Enfortumab

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

Authors: Tanya Jindal et al.

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma

advanced urothelial carcinoma Ajjai Alva Ali Raza Khaki. Amanda Nizam Arnab Basu Cameron Pywell cancer Charles Nguyen Christopher Hoimes Cindy Jiang Deepak Kilari Dimitra Bakaloudi Dory Freeman Emily Lemke Hamid Emamekhoo Joaquim Bellmunt Laura Bukavina Matthew Davidsohn Matthew I. Milowsky Matthew T Campbell Mehmet A Bilen Michael Glover Nancy B. Davis Omar Alhalabi OncoDaily Oncology Pedro C Barata Petros Grivas Rafee Talukder Rohit Bose Sean Evans Shilpa Gupta Sumit A. Shah Tanya Jindal Vadim S Koshkin Woogwang Sim Yousef Zakharia

James Whale Dies at 74: The Radio Icon’s Long Fight Against Kidney Cancer

Top GU Immunotherapy Trials to Watch at ESMO 2025

Julie Gralow Received the 2025 NCG Lifetime Achievement Award in Oncology

FDA Fast Track for CLD-201: Stem Cell–Based Oncolytic Virus for Soft Tissue Sarcoma

Jessica Posada Was Named Inaugural Recipient of the Debbie’s Dream Early Career Investigator Award